About US
Contact us
-
SFDA and the Ministry of Health to take further actions to curb non-drug substance being simulated as drugIn order to crack down on the illegal activities of non-drug substance being simulated as drug and safeguard the public’s health, recently, the State Food and Drug Administration (SFDA) and th2010/6/4
-
Orexigen® Therapeutics Announces FDA Acceptance Of Contrave® New Drug Application For The Treatment Of ObesitySan Diego/PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Adminis2010/6/3
-
Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits For Prostate Cancer Patients Beyond One YearANNOUNCED AT LEADING UROLOGY MEETING San Francisco/PRNewswire/ -- Prostate cancer patients on leuprolide who were offered to continue on FIRMAGON® (degarelix for injection) after one year of trea2010/6/3
-
SBS Biomolecular Screening SymposiumSBS Biomolecular Screening SymposiumAdvanced Applications Across Academia, Government & IndustryOctober 18 -19, 2010 - Sheraton Imperial Hotel & Convention CenterDurham, NC, USAwww.sbsonline.o2010/6/3
-
INSILCO increases capacity of precipitated silicaINSILCO Ltd., India, part of Evonik Industries, Germany, announces a capacity increase for precipitated silica at its production site in Gajraula. The additional capacities will be available by first2010/6/2
-
Oramed Pharmaceuticals Reports Results of Phase IIb Trial of Oral Insulin Administration to Type 2 Diabetes PatientsOramed Pharmaceuticals Inc., a developer of alternative drug delivery systems, recently reported results for its completed Phase IIb non-FDA clinical trial of its flagship oral insulin capsule2010/6/1
-
Marinomed Achieves Preclinical POC for Allergy & Allergic Asthma DrugMarinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, recently announced that MAM-06.301 has achieved preclinical proof-of-conce2010/6/1
-
Genzyme Receives FDA Approval for Lumizyme for Pompe DiseaseGenzyme Corporation recently announced the FDA has granted US marketing approval for Lumizyme (alglucosidase alfa), produced at the 4000-liter bioreactor scale at its manufacturing facility in2010/6/1
-
Transave Issued Key Composition of Matter Patent for ARIKACETransave Inc. recently announced the US Patent and Trademark Office has issued an important composition of matter patent (US Patent No. 7,718,189) for liposomal aminoglycoside formulations, in2010/5/31
-
to-BBB Technologies Announces Brain Drug Delivery Pilot Study with Janssen Pharmaceutica for CNS Diseasesto-BBB, the Dutch drug brain delivery company, recently announced it is entering into a pilot study with Janssen Pharmaceutica NV (Janssen) to enhance delivery of drugs to the brain for Centra2010/5/31